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Background: Prevalence estimates for depression vary considerably by the type of assessment instrument, and
there is limited information on their overlap in population-based samples. Our aim was to compare the Patient
Health Questionnaire-9 (PHQ-9) with the Composite International Diagnostic Interview (CIDI) as measures for current
major depressive syndrome (MDS) in a large population-based sample.
Methods: Data derived from the mental health module of the nationwide cross-sectional German Health Interview
and Examination Survey for Adults (DEGS1-MH) (n = 4483; age 18–79 years). MDS in the past two weeks was
assessed (a) using the PHQ-9 diagnostic algorithm (PHQ-MDS) and (b) based on CIDI information about the latest
symptom occurrence (recency) (CIDI-MDS). Prevalences, overall concordance and percentages of overlap of both
MDS measures were determined. Prevalences of affirmed PHQ-9 depression symptoms and the mean and median
PHQ-9 sum scores were analyzed per measure.
Results: Prevalence of current MDS was 2.7% (95% CI: 2.0-3.6) for PHQ-MDS and 3.9% (95% CI: 3.1-5.0) for CIDI-MDS.
The overall agreement between both measures was moderate (kappa: 0.43). Of all the participants, 1.5% (95% CI:
1.0-2.2) were classified as MDS cases by both measures, with 54.5% (95% CI: 42.7-65.9) of PHQ-MDS cases and 37.9%
(95% CI: 27.8-49.1) of CIDI-MDS cases also being classified as MDS by the respective other MDS measure. However,
94.8% (95% CI: 93.6-95.8) of the participants were classified as non-MDS by both measures, with 97.5% (95% CI:
96.6-98.1) of non-PHQ-MDS and 98.7% (95% CI: 98.2-99.1) of non-CIDI-MDS being classified as non-MDS by the
respective other MDS measure. The mean and median PHQ-9 sum score was higher in those with PHQ-MDS than
in those with CIDI-MDS.
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Conclusions: Both measures have a high level of agreement for ruling out current MDS, but the overlap in their
classification of cases is moderate. Our results indicate that they cannot be interpreted as equal measures of the same
construct, suggesting limited comparability of their prevalence estimates. However, further exploration of algorithms
and correlates and a proper labeling of measures in epidemiological studies are required.
Keywords: Depression, Patient health questionnaire, Composite international diagnostic interview, Population-based
sampleBackground
Depressive disorders are a major public health issue with
far reaching consequences for individuals and society
[1,2]. Reliable and valid information at the population
level is essential for estimating prevalences and associated
care needs. Of the wide range of depressive categories de-
fined in the Diagnostic and Statistical Manual of Mental
Disorders (DSM-IV) [3], major depression is by far the
most prevalent type in the general population [4]. In light
of different research questions and mostly limited inter-
view time, various instruments have been developed for
mental health epidemiology and monitoring that differ in
length, structure, and construct covered (i.e., at the level
of symptoms, syndromes or the full clinical picture).
The Composite International Diagnostic Interview
(CIDI) is an established and widely used instrument for
assessing a clinical diagnosis of major depression in epi-
demiological and clinical studies [5-7]. It has been devel-
oped and validated for determining major depressive
disorder (MDD) according to DSM-IV criteria in the past
12 months and over the lifetime, and major depressive
syndrome (MDS), in which the exclusion criteria for
MDD (i.e., mixed episodes, medical or substance-related
reasons for symptoms, lifetime manic or hypomanic epi-
sodes) are disregarded. However, information about the
latest occurrence, i.e., the recency of symptoms, is used in
diverse studies based on the CIDI to determine a 4-week
diagnosis [8-11]. The CIDI 4-week recency information
for MDD was reported to be highly concordant with the
diagnosis of MDD based on a professional psychiatric
interview in a clinical sample [12], but the validity of
recency information for determining a diagnosis for the
past four weeks or shorter time frames has not yet been
examined in the general population.
The Patient Health Questionnaire-9 (PHQ-9) is another
established and frequently used instrument to assess MDS
in clinical and population-based studies. Although it is
also based on the DSM-IV criteria of major depression,
the PHQ-9 has been specifically developed as a screening
instrument for current depressive symptoms and syn-
dromes in the past two weeks [13,14]. The PHQ-9 diag-
nostic algorithm has been extensively validated in clinical
samples with varying results [15-17], but there are practic-
ally no studies on its diagnostic validity for determiningcurrent MDS with an appropriate reference instrument in
the general population.
In this study, we use data from a large sample of the
adult general population of Germany to explore the
agreement and comparability of the PHQ-9 diagnostic
algorithm and the CIDI information about symptom
recency as measures for MDS in the past two weeks.
Therefore, for both MDS measures, we investigated (1)
the prevalence, (2) the percentages of overlap between
these measures, and (3) the prevalence of single PHQ-9
depression symptoms and the mean and median PHQ-9
sum score. (4) Additionally, we examined the percentage
of PHQ-MDS cases identified as 12-month MDS cases
by the CIDI.Methods
Study design and sample
Cross-sectional data of the mental health module
(DEGS1-MH) of the German Health Interview and Exam-
ination Survey for Adults (DEGS1) (data collection: 2009–
2012) were used. The study design and sample have been
described elsewhere [18-20]. DEGS1 and DEGS1-MH
included a representative sample of community-dwelling
residents of Germany aged 18–79 years. In DEGS1-MH,
25 mental disorders were assessed with the DEGS-CIDI, a
modified version of the German version (DIA-X/M-CIDI)
[7,12] of the World Health Organization CIDI [5,20],
complemented by additional questionnaires including the
PHQ-9. Of the 8151 DEGS1 participants, 6027 were
eligible for DEGS1-MH, and 5317 of these participated in
the DEGS1-MH (conditional response rate: 88.2%) [20].
Of these, 4483 had full mental health interviews (one par-
ticipant withdrew informed consent after publication of
the study protocol), which were conducted by clinically
trained interviewers, of which 94% were clinical psycholo-
gists or advanced clinical psychology students [20]. Partici-
pants with missing data for any of the measures of MDS
were excluded from this study.
The DEGS1 study protocol was consented by the Federal
and State Commissioners for Data Protection and was
approved by the Charité-Universitätsmedizin Berlin ethics
committee (No. EA2/047/08) and by the Ethics Board of
the Technische Universität Dresden for DEGS1-MH (No.
Table 1 Prevalence of MDS and non-MDS according to









1.5 (1.0-2.2) 1.2 (0.9-1.8) 2.7 (2.0-3.6)
Non-MDS
(n = 4196)
2.4 (1.8-3.3) 94.8 (93.6-95.8) 97.3 (96.4-98.0)
Total 3.9 (3.1-5.0) 96.1 (95.0-96.9) 100
1current major depressive syndrome according to the diagnostic algorithm of
the Patient Health Questionnaire-9 (PHQ-9).
22-week major depressive syndrome according to the CIDI information about
symptom recency.
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consent prior to the interviews.
Measures of current MDS
PHQ-9 diagnostic algorithm
The self-administered German version of the PHQ-9
[21] was applied prior to the CIDI depression section.
For each of the nine DSM-IV depression symptoms, the
PHQ-9 assesses how often the respondent has been
bothered by that symptom over the past two weeks,
assigning values of 0 to 3 points (0 - not at all, 1 - several
days, 2 - more than half of the days, 3 - nearly every
day). According to Löwe et al., a case of current major
depressive syndrome (PHQ-MDS) was determined
when at least five symptoms were reported as present
for more than half the days (suicide item: several days
or more) in the past two weeks, including depressed
mood or lack of interest [21].
12-month and 2-week CIDI-MDS
In the DIA-X/M-CIDI, the standard algorithm aggre-
gates thirty single items into the nine DSM-IV depres-
sion symptoms. MDS within the past 12 months is
defined as at least five of the nine symptoms present
most of the days for a minimum of two weeks, including
depressed mood or lack of interest present most of the
time of the day, disregarding additional information on
exclusion criteria such as medication or substance use
or bereavement, which is used in the definition of MDD
[3]. As the 12-month time frame was not appropriate for
assessing current MDS, a CIDI measure for current
MDS was defined in analogy to the algorithm used to
determine 4-week diagnoses of disorders [8-10,22]: MDS
in the past two weeks (CIDI-MDS) was defined as 12-
month MDS with recency of depressed mood or loss of
interest, or tiredness or exhaustion, and “further depression
symptoms” in the past two weeks.
Statistical analysis
Prevalences with 95% confidence intervals (95% CIs) of
PHQ-MDS and CIDI-MDS were estimated. Because of
the lack of a gold standard for current MDS, operational
characteristics (sensitivity and specificity) were not calcu-
lated, but the percentages of overlap between both mea-
sures were calculated. Concordance between the measures
was examined using Cohen’s kappa [23]. Additionally, the
percentage of PHQ-MDS cases identified as 12-month
MDS cases according to the CIDI was examined. Finally,
the prevalence of the single PHQ-9 depression symptoms
present on more than half the days (suicide item: several
days or more) in the past two weeks and the mean PHQ-9
sum scores by MDS measure were calculated. Sex- or age-
specific results were not reported due to the small number
of cases.Differences were considered statistically significant if
the 95% CIs did not overlap. Sample weights were used
to account for participation probability and correcting
sample deviations from population structure (as of Dec
31, 2010) in age, sex, region, nationality, type of munici-
pality and education [20]. Therefore, all figures presented
are weighted population estimates (except the median
PHQ-9 sum score). To account for the clustering of par-
ticipants within sample points, Stata 12.1 survey proce-
dures were used.Results
Of the 4483 DEGS1-MH participants, 126 (2.8%) had
missing values for the PHQ-MDS, 51 (1.1%) for the CIDI-
MDS, and 24 (0.5%) for both measures, leaving a study
sample of n = 4282. Of those, 50.8% (95% CI: 48.8-52.8)
were female, the mean age was 47.8 years (95% CI: 47.2-
48.4), 59.1% (95% CI: 56.7-61.5) were married, 34.5% (95%
CI: 32.0-37.1) had a low education level, and 51.1% (95%
CI: 48.9-53.2) had a medium education level according to
the Comparative Analysis of Social Mobility in Industrial
Nations (CASMIN) [24].Concordance and overlap of the PHQ-MDS and CIDI-MDS
Prevalence of current MDS was 2.7% (95% CI: 2.0-3.6) ac-
cording to PHQ-MDS and 3.9% (95%CI: 3.1-5.0) accord-
ing to CIDI-MDS (Table 1). Overall, 1.5% of participants
(95% CI: 1.0-2.2) were classified as MDS cases and 94.8%
as non-MDS cases by both instruments. The overall agree-
ment between PHQ-MDS and CIDI-MDS was moderate
(kappa: 0.43).
Of those with PHQ-MDS, 54.5% (95% CI: 42.7-65.9)
were classified as CIDI-MDS (Table 2), and of those with
CIDI-MDS, 37.9% (95% CI: 27.8-49.1) were classified as
PHQ-MDS. The percentages of concordant classification
as non-MDS cases were at least 97.4% in both directions.
Of those with PHQ-MDS, 78.8% (95% CI: 67.6-86.72)
were classified as 12-month CIDI-MDS cases.
Table 2 Percentages of overlap of MDS and non-MDS
cases according to PHQ-MDS1 and CIDI-MDS2
% (95% CI)
PHQ-MDS classified as CIDI-MDS 54.5 (42.7-65.9)
Non-PHQ-MDS classified as non-CIDI-MDS 97.5 (96.6-98.1)
CIDI-MDS classified as PHQ-MDS 37.9 (27.8-49.1)
Non-CIDI-MDS classified as non-PHQ-MDS 98.7 (98.2-99.1)
1current major depressive syndrome according to the diagnostic algorithm of
the Patient Health Questionnaire-9 (PHQ-9).
22-week major depressive syndrome according to the CIDI information about
symptom recency.
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Overall, the prevalence of all the PHQ-9 depression
symptoms except “psychomotor retardation or agitation”
was higher among participants with PHQ-MDS com-
pared to those with CIDI-MDS (Table 3). CIDI-MDS
cases were less likely than PHQ-MDS cases to affirm
depressed mood and lack of interest as main depression
symptoms in the PHQ-9. Additional analyses showed
that 58.9% (95% CI: 47.9-69.1) of those with CIDI-MDS
affirmed at least one of these two symptoms. CIDI-MDS
cases had a lower mean and median PHQ-9 sum score
(11.7 and 10.5) than PHQ-MDS cases (15.9 and 15).
Discussion
This study compares two measures of current MDS in
the past two weeks based on the PHQ-9 diagnostic
algorithm and on information of symptom recency from
the CIDI in a large population-based sample of adults in
Germany. Prevalence was 2.7% for PHQ-MDS and 3.9%
for CIDI-MDS. Our analyses showed a moderate overallTable 3 Prevalence of PHQ-9 depression symptoms and mean
and CIDI-MDS2
PHQ-9 depression symptoms present more than half of the days
Little interest or pleasure in doing things
Feeling down, depressed, or hopeless
Trouble falling or staying asleep, or sleeping too much
Feeling tired or having little energy
Poor appetite or overeating
Feeling bad about yourself or that you are a failure or have let yourself or yo
Trouble concentrating on things, such as reading the newspaper or watching
Moving or speaking so slowly that other people could have noticed, or the o
restless that you have been moving around a lot more than usual
Thoughts that you would be better off dead or of hurting yourself in some w
Mean PHQ-9 score
Median PHQ-9 score
1current major depressive syndrome according to the diagnostic algorithm of the P
22-week major depressive syndrome according to the CIDI information about symp
3present at least “several days”.concordance of both, with a high agreement regarding the
classification as non-MDS, but with moderate agreement
in their classification as MDS. CIDI-MDS cases had lower
prevalences of single PHQ-9 items affirmed and a lower
mean PHQ-9 sum score than those with PHQ-MDS.
More than three-quarters of those with PHQ-MDS were
included in the 12-month CIDI-MDS diagnosis.
The difference in prevalence is plausible considering
that the PHQ-9 focuses on the narrow time frame of two
weeks before the assessment, whereas the 2-week CIDI-
MDS comprises those cases of any episode of MDS in the
past 12 months, who reported the past two weeks as the
latest presence of depressed mood or loss of interest or
tiredness/exhaustion and “some further symptoms”.
The moderate percentage of overlap between PHQ-
MDS and CIDI-MDS in the past two weeks appears
remarkable at first sight considering that both instruments
cover the same time frame of the past two weeks and are
based on the criteria of the DSM-IV. In our data, 37.9% of
those with CIDI-MDS were also classified as PHQ-MDS,
which is rather low compared to studies in clinical sam-
ples with the Structured Clinical Interview for DSM-IV
Disorders (SCID) as the reference instrument [14,16].
However, there are several plausible explanations for this
finding. First, depression is likely to be less frequent in the
general population than in clinical samples, and the ability
of the PHQ-9 to detect MDS has been questioned in
samples with low pretest probabilities [16]. Second, milder
forms of depression are likely to be more common in a
general population sample than in a clinical sample, and
the agreement of diagnostic instruments may be lower in
such samples [25-27]./median PHQ-9 score among participants with PHQ-MDS1
PHQ-MDS %
(95% CI) n = 86
CIDI-MDS %
(95% CI) n = 130
68.7 (54.1-80.3) 38.6 (28.5-49.8)
77.1 (63.0-87.0) 42.5 (31.6-54.3)
83.5 (71.4-91.1) 60.9 (49.6-71.1)
97.7 (89.9-99.5) 68.8 (57.5-78.3)
72.8 (60.7-82.2) 41.9 (31.3-53.2)
ur family down 72.1 (59.6-81.9) 39.4 (29.1-50.8)
television 52.2 (39.3-64.8) 34.5 (24.2-46.5)
pposite— being so fidgety or 17.7 (10.5-28.3) 8.3 (4.3-15.3)
ay3 61.0 (46.8-73.6) 41.9 (32.1-52.5)
15.9 (14.9-17.0) 11.7 (10.6-12.8)
15 10.5
atient Health Questionnaire-9 (PHQ-9).
tom recency.
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sible, resulting from differences in the assessment of
symptom severity and in the algorithms applied in the
measures examined. Regarding the PHQ-9, the wording
concerning the temporal pattern of the occurrence of
symptoms is slightly less stringently specified than in the
DSM-IV in that it demands five of nine symptoms to be
present at least half of the days in the past two weeks;
however, it does not specify the presence as “most of the
time of the day” for the main symptoms, as does the
DSM-IV [3] and the CIDI. Thus, PHQ-MDS is likely to
include cases whose main symptoms were potentially less
severe than demanded in the DSM-IV, which might also
explain why 78.8% and not all of those with PHQ-MDS
were identified as 12-month CIDI-MDS cases.
Regarding the CIDI, the presence of the full MDS cri-
teria is assessed for at least two weeks in the past
twelve months but not necessarily for the time indi-
cated in the question about the latest symptom occur-
rence. To determine the recency, potential 12-month
MDS cases were asked to indicate the latest occurrence
of depressed mood or loss of interest or additional
tiredness/exhaustion and “some further symptoms”.
First, this might lead to a classification of current MDS
in respondents with subthreshold depression symp-
toms, which is supported by the finding that the mean
and median PHQ-9 sum scores for 2-week CIDI-MDS
were rather low (11.7 and 10.5) and that the PHQ-9
items on depressed mood and loss of interest as main
depression symptoms were reported substantially less
frequently than in those with PHQ-MDS. Second, 2-
week CIDI-MDS does not include depressed mood and
lack of interest as the only main symptoms; it also
includes loss of interest following the ICD-10 [28]. This
difference between the algorithms of PHQ-MDS and 2-
week CIDI-MDS might be an additional explanation for
the discrepancies found.
The fact that 12-month CIDI-MDS cases do not neces-
sarily experience the full symptomatic picture in the two
weeks prior to the interview is self-evident considering the
episodic course of depression, i.e., the variation of symptom
severity between the full clinical picture and subclinical
symptoms [29,30] or partial remission with or without
treatment.
Limitations
Several limitations must be considered. Firstly, there is
limited information about the diagnostic validity of
PHQ-MDS and 2-week CIDI-MDS based on the infor-
mation about symptom recency in general population
samples; therefore, neither can be considered the gold
standard. Secondly, symptom assessments and algorithms
differ between the measures investigated, confining the
options of identification of reasons for discrepancy.Thirdly, because the definition of MDS does not com-
prise differential diagnosis, MDS according to both
measures might occur in the context of other mental
disorders, e.g., bipolar disorder. Fourthly, because cases
with severe depression symptoms are less likely to par-
ticipate in health surveys, reported prevalences are pre-
sumably conservative with regard to the prevalence of
MDS in the general population in Germany aged 18–79
years.Conclusion
The results suggest that both the PHQ-9 diagnostic
algorithm and CIDI-MDS in the past two weeks may be
useful to rule out current MDS in samples of the general
population. The PHQ-9 may be more useful for general
population surveys with limited interview time because
of its brevity, flexible use as a diagnostic algorithm and
severity score, different validated assessment modes and
frequent worldwide use. Nevertheless, one should con-
sider that the diagnostic algorithm might include depres-
sion cases with less persistent symptoms in the current
episode than are defined in the DSM-IV. Thus, its valid-
ity in screening for or determining current MDS in the
general population must be further examined with an
appropriate reference instrument in a large sample, ana-
lyzing possible sex- and age-specific differences as well.
When using the CIDI recency information as an indica-
tor for the latest clinical diagnosis, researchers should
keep in mind and explicitly discuss that it might include
a considerable number of subthreshold cases, particu-
larly in general population samples. Our findings raise
the question of whether this is also the case with regard
to other time frames based on the recency information.
This question has yet to be investigated with a valid gold
standard to determine to what extent recency informa-
tion can be interpreted as a valid indicator for a clinical
diagnosis. Obviously, this does not affect the CIDI 12-
month perspective, which remains the gold standard for
determining depressive disorders in the past 12 months,
even more so because it also allows determining MDD
diagnosis with exclusion criteria.
The fact that we found only moderate overlap of the
two measures for current MDS, which have both been
developed based on the same criteria, supports other
research showing that even minor wording changes in
depression measures may lead to major changes in
prevalence estimates [31]. Thus, it is important for re-
searchers in the field of depression to carefully describe
and precisely discuss the constructs and time frames
covered by specific depression measures. Additionally,
it is important to use adequate terminology for each
depression measure instead of subsuming any measures
under the general name “depression”.
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